158 related articles for article (PubMed ID: 16175615)
21. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
22. Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2.
Sikuler E; Tur-Kaspa R; Shemer-Avni Y; Delgado J; Zilberman D; Fich A; Baruch Y; Hyam E
J Clin Gastroenterol; 2008 Jul; 42(6):730-3. PubMed ID: 18574394
[TBL] [Abstract][Full Text] [Related]
23. Structural biology of hepatitis C virus.
Penin F; Dubuisson J; Rey FA; Moradpour D; Pawlotsky JM
Hepatology; 2004 Jan; 39(1):5-19. PubMed ID: 14752815
[TBL] [Abstract][Full Text] [Related]
24. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.
Dahari H; Lo A; Ribeiro RM; Perelson AS
J Theor Biol; 2007 Jul; 247(2):371-81. PubMed ID: 17451750
[TBL] [Abstract][Full Text] [Related]
25. Viral dynamics in hepatitis C.
Kershenobich D; Henonin CH
Isr Med Assoc J; 2001 May; 3(5):360-3. PubMed ID: 11411202
[TBL] [Abstract][Full Text] [Related]
26. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
Rong L; Perelson AS
Crit Rev Immunol; 2010; 30(2):131-48. PubMed ID: 20370626
[TBL] [Abstract][Full Text] [Related]
27. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
28. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
Shedlofsky SI
Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
[No Abstract] [Full Text] [Related]
29. Hepatitis C virus therapies.
Smith RE
Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
[No Abstract] [Full Text] [Related]
30. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
Georg GI; Wang S
J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
[No Abstract] [Full Text] [Related]
31. Hepatitis C viral kinetics: the past, present, and future.
Chatterjee A; Smith PF; Perelson AS
Clin Liver Dis; 2013 Feb; 17(1):13-26. PubMed ID: 23177280
[TBL] [Abstract][Full Text] [Related]
32. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
Ippolito G; Capobianchi MR; Lanini S; Antonelli G
Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
[TBL] [Abstract][Full Text] [Related]
33. New hepatitis C therapies.
Pawlotsky JM
Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
[No Abstract] [Full Text] [Related]
34. Hepatitis C viral kinetic models.
Herrmann E; Zeuzem S
Cell Death Differ; 2003 Jan; 10 Suppl 1():S7-8. PubMed ID: 12655337
[No Abstract] [Full Text] [Related]
35. Viral kinetics in hepatitis C.
Lutchman G; Hoofnagle JH
Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
[No Abstract] [Full Text] [Related]
36. Novel therapies for hepatitis C virus based on lessons from virology.
Glenn JS
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S86-8. PubMed ID: 16234068
[TBL] [Abstract][Full Text] [Related]
37. Viral kinetics and mathematical models.
Perelson AS
Am J Med; 1999 Dec; 107(6B):49S-52S. PubMed ID: 10653457
[TBL] [Abstract][Full Text] [Related]
38. The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.
Li Y; Yamane D; Masaki T; Lemon SM
Nat Rev Microbiol; 2015 Sep; 13(9):544-58. PubMed ID: 26256788
[TBL] [Abstract][Full Text] [Related]
39. vRNA structured population model for Hepatitis C Virus dynamics.
Woot de Trixhe X; Krzyzanski W; De Ridder F; Vermeulen A
J Theor Biol; 2015 Aug; 378():1-11. PubMed ID: 25912382
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C Viral Kinetics in Special Populations.
Dahari H; Layden-Almer JE; Perelson AS; Layden TJ
Curr Hepat Rep; 2008; 7(3):97-105. PubMed ID: 19148305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
